Clinical use of dornase alfa is associated with a slower rate of FEV 1 decline in cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, David J. Pasta, Stefanie J. Millar, Joan R. Jacobs, Ashley Yegin, Wayne J. Morgan

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Fingerprint Dive into the research topics of 'Clinical use of dornase alfa is associated with a slower rate of FEV <sub>1</sub> decline in cystic fibrosis'. Together they form a unique fingerprint.

Medicine & Life Sciences